Product Spotlight

What is PT-141? (Bremelanotide)

Bremelanotide, formerly code-named PT-141, which is also the more common nickname, is a peptide melanocortin receptor agonist.  Melanocortin receptors are members of the rhodopsin family of 7-transmembrane G protein-coupled receptors. Rhodopsin is a light sensitive receptor protein that helps eyes see pigment and color.  Melanocortin receptors don’t just deal with light though. Sexual dissertation, mood, and skin tones can all be affected by melanocortin receptors. Agonists are chemicals that bind to receptors and influence responses based on chemical reaction.

In other words, PT-141 is stronger peptide developed from melanocortin peptides.

Initial Intent

Remember that peptide studies are relatively new.  Scientists and the medical community have only been studying peptides thoroughly for the past 25 or 30 years.  Initially, PT-141 was being developed to influence skin pigment. Viewed as a potential sunless tanning agent, PT-141 was soon recognized to have other side effects that couldn’t be ignored…

Side Effects?

Yes, side effects.  The most common of which appeared to be sexual arousal.  See why it couldn’t be ignored? Male test subjects would experience seemingly spontaneous and uncontrollable erections.  Both male and female subjects would experience suppressed appetites and enhanced libido.

Looking for the Silver Lining…

The medical field specialists are nothing if not resourceful.  PT-141’s side effects have been taken and forced into a positive.  By the 2000’s, studies were being approached regarding the use of PT-141 in individuals struggling with sexual dysfunction.  Two separate study results showed that rapid doses increased erectile activity in male subjects and improved sex drive in premenopausal women.  Sexual desire and arousal were noticeably enhanced in both genders.

PT-141 has most recently been a used as the active ingredients in medications created for individuals suffering form a lack of sex drive, males suffering from erectile disfunction, and females suffering from female sexual dysfunction.

Risks

Unfortunately, PT-141 isn’t exactly stable yet.  There are a variety of risks involved when test subjects are introduced PT-141 or Bremelanotide.  Prolonged use seems to exacerbate these problems. A number of use cases have shown test subjects suffer from depression-like symptoms after continued use of PT-141.  Since PT-141 alters hormone levels, it’s not surprising that there could be some adverse side mental side effects.

A study published in mid-2009 showed that risk factors seemed to include hypertension, weight gains, dyslipidemia, and cardiovascular disease.  The varying risks seem to be revolved around a plethora of complex reactions that take place between the PT-141 and pre-existing medications or substances.  Clearly more research needs to be done before wide distribution.

Future

The increase in sexual desire and elevated levels of energy realized from PT-141 supplementation is going to lead to some spectacular medication in the future.  For now, more research needs to be done so that we can get rid of the side effects and limit the risks involved with human supplementation. If you’re interested in acquiring some raw PT-141 for your own tests, we certainly can provide; Just keep the risks in mind.

  1. Molinoff, P B, et al. “PT-141: a Melanocortin Agonist for the Treatment of Sexual Dysfunction.” Current Neurology and Neuroscience Reports., U.S. National Library of Medicine, June 2003, www.ncbi.nlm.nih.gov/pubmed/12851303.

2. Diamond, L E, et al. “An Effect on the Subjective Sexual Response in Premenopausal Women with Sexual Arousal Disorder by Bremelanotide (PT-141), a Melanocortin Receptor Agonist.” Current Neurology and Neuroscience Reports., U.S. National Library of Medicine, July 2006, www.ncbi.nlm.nih.gov/pubmed/16839319.

3. Stephen H. King, Alexander V. Mayorov, Preeti Balse-Srinivasan, Victor J. Hruby, Todd W. Vanderah, Hunter Wessells, et al. “Melanocortin Receptors, Melanotropic Peptides and Penile Erection.” Current To Med Chem., U.S. National Library of Medicine, June 2009, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2694735/.

Leave a Reply